Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion

https://doi.org/10.1016/j.ymgme.2015.12.002Get rights and content

Highlights

  • The RTB plant lectin is proposed as a carrier for lysosomal replacement enzymes.

  • Plant-made β-gal:RTB fusions retain galactosidase and lectin-binding activities.

  • β-gal:RTB reduces lysosomal GM1 ganglioside levels in GM1 patient fibroblasts.

  • β-gal:RTB undergoes lysosomal β-gal proteolytic activation in GM1 fibroblasts.

  • Dynamics of GM1 correction of β-gal:RTB differs from mammalian cell-derived β-gal.

Abstract

New enzyme delivery technologies are required for treatment of lysosomal storage disorders with significant pathologies associated with the so-called “hard-to-treat” tissues and organs. Genetic deficiencies in the GLB1 gene encoding acid β-galactosidase lead to GM1-gangliosidosis or Morquio B, lysosomal diseases with predominant disease manifestation associated with the central nervous system or skeletal system, respectively. Current lysosomal ERTs are delivered into cells based on receptor-mediated endocytosis and do not effectively address several hard-to-treat organs including those critical for GM1-gangliosidosis patients. Lectins provide alternative cell-uptake mechanisms based on adsorptive-mediated endocytosis and thus may provide unique biodistribution for lysosomal disease therapeutics. In the current study, genetic fusions of the plant galactose/galactosamine-binding lectin, RTB, and the human acid β-galactosidase enzyme were produced using a plant-based bioproduction platform. β-gal:RTB and RTB:β-gal fusion products retained both lectin activity and β-galactosidase activity. Purified proteins representing both fusion orientations were efficiently taken up into GM1 patient fibroblasts and mediated the reduction of GM1 ganglioside substrate with activities matching mammalian cell-derived β-galactosidase. In contrast, plant-derived β-gal alone was enzymatically active but did not mediate uptake or correction indicating the need for either lectin-based (plant product) or mannose-6-phosphate-based (mammalian product) delivery. Native β-galactosidase undergoes catalytic activation (cleavage within the C-terminal region) in lysosomes and is stabilized by association with protective protein/cathepsin A. Enzymatic activity and lysosomal protein processing of the RTB fusions were assessed following internalization into GM1 fibroblasts. Within 1–4 h, both β-gal:RTB and RTB:β-gal were processed to the ~ 64 kDa “activated” β-gal form; the RTB lectin was cleaved and rapidly degraded. The activated β-gal was still detected at 48 h suggesting interactions with protective protein/cathepsin A. Uptake-saturation analyses indicated that the RTB adsorptive-mediated mechanisms of β-gal:RTB supported significantly greater accumulation of β-galactose activity in fibroblasts compared to the receptor-mediated mechanisms of the mammalian cell-derived β-gal. These data demonstrate that plant-made β-gal:RTB functions as an effective replacement enzyme for GM1-gangliosidosis — delivering enzyme into cells, enabling essential lysosomal processing, and mediating disease substrate clearance at the cellular level. RTB provides novel uptake behaviors and thus may provide new receptor-independent strategies that could broadly impact lysosomal disease treatments.

Introduction

GM1-gangliosidosis is a lysosomal storage disease (LSD) linked to mutations in the GLB1 gene that encodes lysosomal acid β-D-galactosidase (β-gal; EC 3.2.1.23) [1]. The hallmark of GM1-gangliosidosis (GM1) is the progressive buildup of glycosphingolipid GM1 ganglioside, particularly in neurons, which results in widespread neurodegeneration. Some therapeutic modalities (e.g. substrate reduction therapy, and ex vivo and in vivo gene therapies) have been implemented in the animal model [2], [3], [4], [5], [6]. Enzyme replacement therapies (ERTs) have been efficacious for many LSDs [7], [8], [9], an effective ERT has not yet been developed or tested for this disease. Barriers for development of effective ERTs for GM1 and other lysosomal diseases with strong central nervous systems (CNS) involvement remain a) the need to deliver corrective enzyme doses to the brain and b) the continued high cost of developing recombinant protein-drugs and bringing them to patients (reviewed [10], [11]). In this study, we tested a lectin-based “enzyme delivery module” providing receptor-independent routes of cell entry and used a rapid transient plant-based expression platform with the potential to address bioproduction costs.

All currently approved lysosomal disease ERTs exploit either the mannose-6-phosphate receptor (M6PR) or the high-mannose receptor (MMR) to direct endocytosis and lysosomal delivery of the corrective enzyme. While effective in treating visceral disease manifestations, these products do not effectively cross the blood–brain-barrier (BBB) to treat pathologies of the CNS and show limited correction in other so-called “hard-to-treat” tissues such as heart, lung and eye. In contrast to receptor-mediated endo/transcytosis, the plant lectin RTB initiates endocytotic uptake primarily by binding to the abundant galactose-terminated glycoproteins and glycolipids present on mammalian cell surfaces, exploiting all known endocytic mechanisms to access cells [12], [13]. This non-specific adsorptive-mediated endocytosis may provide an alternative enzyme delivery strategy with broader biodistribution and the potential to impact pathologies of these “hard-to-treat” tissues [14]. The lectin RTB (ricin toxin B-subunit) is the non-toxic carbohydrate-binding subunit of ricin that is responsible for mediating transport both into and within target cells. The uptake and trafficking of RTB, a galactose/galactosamine-specific lectin from Ricinus communis, has been extensively studied [15], [16], [17], [18]. RTB has high affinity for surface glycolipids and glycoproteins providing access to a broad array of cells and enters cells by multiple endocytotic routes (e.g., clathrin-dependent and -independent; dynamin-dependent and -independent; caveolae-dependent and -independent; macropinocytosis; MMR-mediated) [15], [16], [17], [18]. Upon endocytosis, RTB traverses preferentially to lysosomes or cycles back to the cell membrane (transcytosis pathway), with less than 5% moving “retrograde” to the endoplasmic reticulum (route for delivery of the RTA ribosome-inactivating toxic subunit) [15], [19], [20]. In vivo toxicity studies with the ricin toxin show injected or ingested ricin is quickly mobilized to both blood and lymphatic systems and accumulates in the spleen, liver, kidneys, heart, thymus, brain, and other tissues [21], [22] (reviewed in [23]). Additional studies show that the non-toxic RTB subunit (i.e., without the RTA subunit) mediates uptake into cells and tissue [24], [25], [26]. We therefore hypothesize that RTB will facilitate delivery of genetically associated human β-galactosidase to the critical sites of GM1 pathology. As a first step in testing this, we produced fusion proteins of RTB and human β-gal in plants and characterized their activities in plant tissues and in GM1 patient fibroblasts.

β-gal functions as an exoglycosidase, removing β-1,4-linked galactose residues from glycoproteins sphingolipids such as GM1 ganglioside, and keratan sulfate. Depending on the genetic mutation, β-gal deficiencies can lead to the primarily neurodegenerative GM1 gangiolosidosis or to Morquio B disease [27], [28]. β-gal can be isolated from mammalian tissues as a monomer, dimer, tetramer and as part of a multi-enzyme complex with N-acetyl-α-neuraminidase (Neu1) and the serine peptidase protective protein/cathepsin A (PPCA) [29], [30], [31]. This multi-enzyme complex is critical for enzyme stability and function within lysosomes, as defects in PPCA lead to galactosialidosis disease and deficiencies in both Neu1 and β-gal levels. β-gal is synthesized as an 85 kDa glycoprotein and is proteolytically processed within the lysosome to a 64 kDa “active” form by cleavage of 134 a.a. from the C-terminal end [30]. In PPCA deficient cells, β-gal is synthesized and traffics to lysosomes. However, it is rapidly degraded in lysosomes suggesting that PPCA plays a critical role in stabilizing β-gal in a way that allows the specific catalytic activation events but prevents further degradation [32], [33]. To date, neither plant-based production of functional human β-gal nor production of bioactive β-gal fusions with large heterologous protein domains (mammalian cell-derived HIS-tagged version are available) has been reported.

Plant-based bioproduction provides advantages in safety (no adventitious viral contamination) and cost of manufacture compared to mammalian cell-based technologies [34]. It was initially demonstrated that plants can produce fully functional human lysosomal hydrolases in the early 1990s [70]. The first commercialized plant-made pharmaceutical protein to receive FDA approval for systemic administration was the glucocerebrosidase ERT for Gaucher disease produced in carrot cells (Protalix′ Elelyso, approved in 2012). This product has been used for patient treatment since 2007 [35] with no increase in immunogenicity compared to CHO-cell derived product [36], [37], [38]. In this study, we employ plant-based biomanufacture using transient expression in Nicotiana benthamiana. Briefly, gene vectoring components are infiltrated into leaves of intact plants and recombinant proteins are recovered in 3–7 days (e.g. [39], [40], [41]). Both monoclonal antibodies (e.g. the ZMapp MAb cocktail for treatment for Ebola) and human virus-like particles (e.g. VLP for influenza A) made with the N. benthamiana system are currently in human clinical trials highlighting its potential to make and assemble complex protein products at scale and purity that meet regulatory standards [34], [40], [41], [42], [43], [44]. Thus, this production platform may facilitate more cost-effective development of complex biologics for rare diseases.

We recently reported plant-based production of RTB fusions to the human α-L-iduronidase enzyme (ERT for mucopolysacchardosis I; MPS I) [24]. The fusion product retained both RTB lectin selectivity and iduronidase enzyme activity. The RTB:iduronidase fusion was efficiently taken up into MPS I patient fibroblasts, corrected the lysosomal phenotype, and reduced the glycosaminoglycan disease substrate to “normal” levels by MMR- and M6PR-independent mechanisms [24]. In the present study, β-gal, with and without RTB, was expressed in plants and purified proteins were analyzed for activity, catalytic processing and lysosomal disease correction of GM1 fibroblasts. RTB fusion orientations were developed that supported the complex post-translational processing and multiple protein–protein interaction required for full β-gal functionality within lysosomes and effectively corrected GM1-gangliosidosis at the cell level.

Section snippets

GLB1 cloning

The native GLB1 coding sequence (GLB1, GenBank accession no. NM 000404) and tobacco-codon optimized GLB1 were synthesized (GeneArt®, Life Technologies). Synthesized genes included an adapter carrying a hexa-histidine tag (His) and a stop codon at the 3′-end. These constructs, which harbor the endogenous human signal peptide (hSP), were cloned into a pMK-RQ vector. GLB1 sequences encoding the mature β-gal were also cloned into a pBC-SK(−) vector with an in-house patatin optimized signal peptide

Production of β-gal and β-gal fusions with RTB in N. benthamiana leaves

In lysosomes, β-gal activity is based both on interactions with diverse substrates (e.g., sphingolipids, glycoproteins, keratan sulfates) as well as other proteins, including Neu1, PPCA, and the proteinase responsible for catalytic activation. Although the protein structure of β-gal has been determined [57], it is difficult to predict the structural impact of introducing a large fusion partner such as RTB. RTB itself is a 34 kDa glycoprotein with two distinct galactose/galactosamine binding

Discussion

ERTs have revolutionized patient care and greatly enhanced patient quality of life for a number of lysosomal storage diseases. However, the inability of current ERT approaches to address neurological pathologies limits application to GM1-gangliosidosis, which presents with severe CNS involvement. The plant lectin RTB directs uptake primarily by adsorptive-mediated endocytosis, providing the potential to mediate ERT delivery into tissues and cell types with fundamentally different

Author contributions

C.L.C, D.N.R., J.C. and W.A. participated in project conceptualization and research strategy development; J.C. and V.K designed and produced the gene constructs; J.A. and A.F. expressed, purified, and characterized the plant-produced proteins with assistance in biochemical characterization from J.R.; W.A. developed the Dual bioactivity assay, enzyme kinetic studies, and all human cell-based assays with assistance in cell culture and related assays from R.M.; C.L.C., W.A., J.C., and J.A. wrote

Conflict of interest

C.L.C and D.N.R. are co-founders of biotech start-up BioStrategies LC. The other authors declare no competing financial interests.

Acknowledgments

We wish to thank Drs. Alessandra d'Azzo, Erik Bonten and Ida Annunziata at St. Jude Children's Research Hospital for valuable insights, discussion and support in the development of this work. We also thank Samantha Davis for her help in plant growth and transfection. This research was supported by funding to BioStrategies LC from an NIH/NINDS Phase I SBIR grant (1R43NS084565-01) and the National Tay-Sachs and Allied Diseases Association.

References (70)

  • B. Stechmann et al.

    Inhibition of retrograde transport protects mice from lethal ricin challenge

    Cell

    (2010)
  • F. Medina-Bolivar et al.

    A non-toxic lectin for antigen delivery of plant-based mucosal vaccines

    Vaccine

    (2003)
  • J.W. Callahan

    Molecular basis of GM1 gangliosidosis and Morquio disease, type B. Structure-function studies of lysosomal beta-galactosidase and the non-lysosomal beta-galactosidase-like protein

    Biochimica et Biophysica Acta

    (1999)
  • E.J. Bonten et al.

    Lysosomal neuraminidase. Catalytic activation in insect cells is controlled by the protective protein/cathepsin A

    J. Biol. Chem.

    (2000)
  • A. van der Spoel et al.

    Processing of lysosomal beta-galactosidase. The C-terminal precursor fragment is an essential domain of the mature enzyme

    J. Biol. Chem.

    (2000)
  • A.V. Pshezhetsky et al.

    Direct affinity purification and supramolecular organization of human lysosomal cathepsin A

    Arch. Biochem. Biophys.

    (1994)
  • O.P. van Diggelen et al.

    Enhanced proteolytic degradation of normal β-galactosidase in the lysosomal storage disease with combined β-galactosidase and neuraminidase deficiency

    Biochim. Biophys. Acta

    (1982)
  • H. Du et al.

    Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice

    J. Lipid Res.

    (2008)
  • A. Zimran et al.

    Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

    Blood

    (2011)
  • G. Pastores et al.

    Plant cell-expressed recombinant glucocerebrosidase: Taliglucerase alfa as therapy for Gaucher disease in adults patients previously treated with imiglucerase: 24-month results

    Mol. Genet. Metab.

    (2013)
  • G.A. Grabowski et al.

    Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology

    Mol. Genet. Metab.

    (2014)
  • M. Nicolaisen et al.

    The 5′ untranslated region from pea seedborne mosaic potyvirus RNA as a translational enhancer in pea and tobacco protoplasts

    FEBS Lett.

    (1992)
  • W.S. Prince et al.

    Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase

    J. Biol. Chem.

    (2004)
  • G.N. Sando et al.

    Recognition and receptor-mediated uptake of a lysosomal enzyme, alpha-l-iduronidase, by cultured human fibroblasts

    Cell

    (1977)
  • U. Ohto et al.

    Crystal structure of human β-galactosidase: structural basis of Gm1 gangliosidosis and morquio B diseases

    J. Biol. Chem.

    (2012)
  • V. Gomord et al.

    Posttranslational modification of therapeutic proteins in plants

    Curr. Opin. Plant Biol.

    (2004)
  • W.M. Pardridge

    Molecular Trojan horses for blood–brain barrier drug delivery

    Curr. Opin. Pharmacol.

    (2006)
  • R.G. Thorne et al.

    Quantitative analysis of the olfactory pathway for drug delivery to the brain

    Brain Res.

    (1995)
  • C. Bies et al.

    Lectin-mediated drug targeting: history and applications

    Adv. Drug Deliv. Rev.

    (2004)
  • S. Shen et al.

    Terminal N-linked galactose is the primary receptor for adeno-associated virus 9

    J. Biol. Chem.

    (2011)
  • Y. Suzuki et al.

    b-Galactosidase deficiency (b-galactosidosis): GM1 gangliosidosis and Morquio B disease

  • J.L. Kasperzyk et al.

    N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis

    J. Neurochem.

    (2004)
  • R.C. Baek et al.

    AAV-mediated gene delivery in adult GM1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival

    PLoS One

    (2010)
  • E.D. Kakkis et al.

    Enzyme-replacement therapy in mucopolysaccharidosis I

    N. Engl. J. Med.

    (2001)
  • M. Beck

    Therapy for lysosomal storage disorders

    IUBMB life

    (2010)
  • Cited by (44)

    • Therapies for lysosomal storage diseases: Principles, practice, and prospects for refinements based on evolving science

      2022, Molecular Genetics and Metabolism
      Citation Excerpt :

      The ricin toxin subunit B (RTB) recognizes galactose and galactosamine residues on any cellular membrane [82], is non-toxic, and is poorly antigenic. Mouse model studies with α-L-Iduronidase-RTB and β-galactosidase-RTB fusion proteins in MPS IH and β-galactosidase for GM1-gangliosidosis showed delivery to many tissues, including the CNS, with decreases in storage materials and decreased overall pathology [83–85]. The fusion protein enters the cell and is delivered to the lysosome, where RTB is cleaved from the COOH-end of the enzyme and is degraded [82,84,85].

    • Examination of a blood-brain barrier targeting β-galactosidase-monoclonal antibody fusion protein in a murine model of GM1-gangliosidosis

      2021, Molecular Genetics and Metabolism Reports
      Citation Excerpt :

      In addition to the stability of the human β-gal enzyme, the lack of therapeutic efficacy of mTfR-GLB1 could be due to the structure of the mTfR-GLB1 protein. Studies have shown that the presence or location of the receptor-binding component of the engineered enzyme can significantly impact enzyme activity, for example, in β-glucuronidase [23], which is the deficient enzyme in the lysosomal disease MPS VII (Sly syndrome), and β-galactosidase in GM1-gangliosidosis [9]. In vitro studies showed that the synthetic mTfR-GLB1 enzyme, which is comprised of two human β-gal enzymes, had 17% of the β-gal enzyme activity as the recombinant human β-gal enzyme (unpublished data, Tanabe Research Laboratories USA, Inc.).

    View all citing articles on Scopus
    1

    J.C., W.A., and J.A. contributed equally and should be consider co-first authors on this work.

    2

    Present address: Hematology Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.

    View full text